Nah man, oto-313 for tinnitus will be phase 1/2. They have already demonstrated safety. I'm waiting to hear if @David from BTA saw there presentation from ARO-2019
Otonomy is a strong company with plenty of cash. Much talk is on Frequency but Otonomy have a strong pipeline of products for various ear disorders in testing.
Otonomy will be the ONLY company with 3 indications (HL, T & V) in pipeline in 2019 in trials. Any idea when a Q&A with them @Markku, 2019 will be an interesting year for them and us.
